Clinical trials: Previously Treated Non Small Cell Lung Cancer
Non-small Cell Lung Cancer
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Pemetrexed is an FDA-approved treatment for advanced lung cancer but the response rate is still very low. Bortezomib is currently approved to treat myeloma in patients who have already been treated.
- Trial name
- NCT00516100
- Testing
- bortezomib
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aptium Oncology Research Network
Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug.
- Conditions
- Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer
- Trial name
- NCT02661100
- Testing
- Pembrolizumab, CDX-1401, Poly-ICLC
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet…
- Trial name
- CheckMate 078 (NCT02613507)
- Testing
- Nivolumab, Docetaxel
- Where
- 33 sites in China, Hong Kong and 2 more
- Volunteers
- 504 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ
This is a randomized, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of SYS6010 versus docetaxel in participants with Locally Advanced or Metastatic EGFR Wild-type Non-squamous…
- Trial name
- SYNSTAR03 (NCT07442565)
- Testing
- SYS6010, Docetaxel
- Volunteers
- 506 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Non-Small Cell Lung Cancer
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy
The purpose of this study is to establish the objective response rate (complete response + partial response), following treatment with Alimta plus VELCADE, Alimta alone, or VELCADE alone in patients with locally advanced or…
- Trial name
- NCT00343720
- Testing
- VELCADE, Alimta
- Where
- Belgium
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
This phase II trial tests how well trabedersen (OT-101) in combination with atezolizumab works in treating patients with non-small cell lung cancer (NSCLC) that has spread from where it first started (lung) to other places in the…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT05935774
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- United States
- Sponsor
- University of Washington
Non-small Cell Lung Cancer
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
The purpose of this study is to determine the efficacy and the toxicities of the study drug PD0332991 in the treatment of patients with Stage IV non-small cell lung cancer with wildtype retinoblastoma protein (RB) and inactivated…
- Trial name
- NCT01291017
- Testing
- PD0332991
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Florida
Non Small Cell Lung Cancer
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
This research is being done because further research on selumetinib in combination with standard chemotherapy treatment is needed.
- Trial name
- NCT01783197
- Testing
- Paclitaxel, Carboplatin, Selumetinib
- Where
- 4 sites in Canada
- Volunteers
- 39 people
- Sponsor
- Canadian Cancer Trials Group
Carcinoma, Non-Small-Cell Lung
LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
The primary objective of this randomized, open-label, active-controlled, multi-center trial is to determine the efficacy of BIBW 2992 given as an add-on to chemotherapy in patients with NSCLC Stage IIIb or IV progressing after…
- Trial name
- NCT01085136
- Testing
- Investigator´s choice of chemotherapy, BIBW 2992
- Where
- 97 sites in Argentina, Australia and 21 more
- Volunteers
- 1,154 people
- Sponsor
- Boehringer Ingelheim
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer…
- Trial name
- NCT07393555
- Testing
- Biospecimen Collection, Computed Tomography, Ivonescimab
- Where
- 41 sites in United States
- Volunteers
- 117 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
This partially randomized phase II trial studies how well nivolumab, cabozantinib s-malate, and ipilimumab work in treating patients with stage IV non-small cell lung cancer that has come back.
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03468985
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- 468 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs.
- Trial name
- NCT07459751
- Testing
- HLX43, HLX43+HLX07, Docetaxel
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Non-Squamous Cell Non-small Cell Lung Cancer
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based…
- Trial name
- CheckMate057 (NCT01673867)
- Testing
- Nivolumab, Docetaxel
- Where
- 119 sites in United States, Argentina and 20 more
- Volunteers
- 582 people
- Sponsor
- Bristol-Myers Squibb
Squamous-cell Non-Small-cell Lung Cancer
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients.
- Trial name
- NCT04171284
- Testing
- SCT-I10, Docetaxel
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sinocelltech Ltd.
Non-Small Cell Lung Cancer, Carcinoma
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
This first time in human study is intended for men and women at least 18 years of age who have advanced lung cancer which has grown or returned after being treated.
- Trial name
- NCT02592577
- Testing
- Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 28 people
- Sponsor
- Adaptimmune
Non-Small Cell Lung Cancer
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously…
- Trial name
- KontRASt-02 (NCT05132075)
- Testing
- JDQ443, docetaxel
- Where
- 51 sites in United States, Argentina and 23 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00365547
- Testing
- bevacizumab, topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
This single-arm, open-label, phase II clinical study aims to evaluate the progression-Free Survival (PFS) of the combination of Alectinib plus Bevacizumab in untreated and first and second-line chemotherapy failed subjects with…
- Trial name
- NCT03779191
- Testing
- Alectinib, Bevacizumab
- Where
- Mexico
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non-small Cell Lung Cancer Metastatic
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Primary Objectives: Study was designed with multiple primary endpoints analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS]) Study…
- Trial name
- CARMEN-LC03 (NCT04154956)
- Testing
- SAR408701, Docetaxel
- Where
- 169 sites in United States, Argentina and 24 more
- Volunteers
- 389 people
- Sponsor
- Sanofi